An Ode to the O.G. Collagen Face Cream
Is the Elemis Pro-Collagen Marine Cream Worth It?
Its well-rounded ingredient list (centered around sustainably-sourced, plant and marine actives) makes it an attractive buy; its SPF-infused variant is also one of our favorite wrinkle creams. "Wrinkle creams should offer both moisturizing and anti-aging properties," Dr. Camp explains, recommending consumers to look for ingredients like hyaluronic acid, ceramides, glycerin, and shea butter to improve moisture retention; plus niacinamide, algae, retinols, bakuchiol, and botanicals with antioxidant properties to help minimize the appearance of fine lines and wrinkles. Elemis's offering is packed with efficacious ingredients apt for that hydration, plumping, and repair you crave for real results.
According to Dr. Camp, 'this product is appropriate for use by those looking to treat and prevent signs of aging, such as crepey skin, fine lines, and wrinkles. In addition to being an option for those with mature skin, this product can also be used by those simply looking for an effective moisturizer.'
My Experience With the Elemis Pro-Collagen Marine Cream
Like any of the leading luxury cosmetics on the market, a sensorial experience is a must, and Pro-Collagen Marine Cream certainly delivers. Its silky cream texture feels weightless on the skin, layering well with other products in my routine. This is the feature that keeps me reaching for it nightly—it's hard to find a face moisturizer that toes the line of lasting nourishment without greasiness (which would exacerbate my skin's oiliness) or stickiness. Exceptionally gentle, I know my skin will remain calm and balanced no matter what else my routine called for that evening.
At 30, I can't yet personally speak to this product's ability to smooth wrinkles, but I can say that it has enhanced my skin's firmness, bounce, and glow, which Dr. Spearman says is to be expected. 'Some early improvements, such as smoother texture or better hydration, can appear quickly, but deeper changes like reduced fine lines or improved firmness usually take more time,' she says. 'Ingredients that support collagen and skin repair often need at least four to eight weeks of consistent use to show noticeable results. Using the product regularly and giving it time is important for the best outcome.'
Via notes of rose and mimosa, the scent here is meant to add to the application experience. 'Aromatherapy is an important part of our heritage: we believe in the power of engaging all the senses on your skin wellness journey," per the brand. I find the scent delicate, refreshing, and spa-like, though that may not be best for some skin types. 'The presence of fragrance (parfum) in the formula may cause irritation for those with sensitive or reactive skin,' Spearman says. 'Because of this, patch testing is recommended to ensure the product is well tolerated.' But if you're like me and delight in feminine floral, you're in for a treat.
Those interested in reaping these benefits can shop the classic cream, or other offerings from its Pro-Collagen line, including its SPF 30, night cream, or cleansing balm—each of which harnesses the power of the sea to yield a healthier, more youthful complexion.
Shop more of Vogue's favorite Elemis products below.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK, August 19, 2025--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. "The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities," said TNF President and Chief Medical Officer, Mitchell Glass, M.D. "We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage." The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts Investor Contact: Sign in to access your portfolio
CBS News
7 minutes ago
- CBS News
Michigan lawmakers call on HHS to explain withholding funds for disability advocate groups
A group of Michigan lawmakers is calling on the Department of Health and Human Services to explain why it took back more than $130,000 in funds that were earmarked for legal support for those with disabilities. Whether it's dealing with insurance or getting legal support for abuse, neglect, or human rights cases, these lawmakers say those with disabilities could be on their own if these funds don't come through. "Attacks like this take us back and repeal so much of the progress that we've made," said Democratic U.S. Rep. Hillary Scholten. Scholten is one of those representatives who say they're looking to hold HHS accountable for withholding these funds. The organization receiving them, Disability Rights Michigan, says in part, "The pullback of these funds threatens our ability to investigate abuse and neglect, ensure safe and appropriate discharges, and advocate for children and adults who depend on Disability Rights Michigan for legal protections." Scholten says withholding funds defeats the purpose of having a resource like this. "A program like that can only continue to exist if we have a full pot of resources available to help individuals with these severe disabilities," she said. Fellow Democratic U.S. Rep. Shri Thanedar also signed the letter, which raised several questions about why the funds were rescinded, when and if they can expect them to be awarded, and why the distribution changed from a lump sum amount to being released as installments. "I signed onto that letter so we can get some answers on the programs being gutted and demand those funds be released for the sake of every American," Thanedar said. These lawmakers are giving HHS 30 days to respond to their questions before they take further action. CBS News Detroit reached out to HHS for comment.
Yahoo
34 minutes ago
- Yahoo
Union calls continued delay of silica dust rule a ‘death sentence' for coal miners in Pa. and beyond
Gary Hairston (from left to right), Judy Riffe, Dianna Perdue and Roosevelt Neal, stand outside of an office building for the U.S. House of Representatives last year. The advocates for people with black lung were in the U.S. Capitol encouraging lawmakers to support coal miners with the incurable disease. (Quenton King | Courtesy photo) Representatives with the United Coal Workers of America have condemned a federal court's decision to continue delaying the implementation of a federal rule to lower coal miners' exposure to dangerous silica dust, calling the pushback 'bureaucratic cowardice.' The silica dust rule — finalized under the U.S. Department of Labor and the Mine Safety and Health Administration last year — should have gone into effect on Monday after being delayed for the first time in April. But now the rule has yet again been pushed back to at least October due to a previous temporary injunction issued by the U.S. Court of Appeals for the Eighth Circuit in response to a request from the National Sand, Stone and Gravel Association to block the rule's implementation completely. The rule would have gone into effect on Monday only for coal mines; the NSSGA — along with several other industry groups who joined the organization in its request — would not have been impacted by the new regulations until 2027, per the rule. SUPPORT: YOU MAKE OUR WORK POSSIBLE Meanwhile, as the rule is delayed, more and more coal miners are working in dusty conditions known to cause and exacerbate black lung disease. 'This is bureaucratic cowardice, plain and simple,' said UMWA International Secretary-Treasurer Brian Sanson. 'We've buried too many friends, too many fathers, and too many sons because of black lung. Bowing to corporate interests doesn't solve the problem; it puts more miners at risk. The science is clear, the rule is needed, and the delay is shameful.' Other industries have had similar protections in place for their workers for years due to settled science showing the dangers posed by constant exposure to silica dust. 'This delay is simply a death sentence for more miners,' said UMWA International President Cecil E. Roberts. 'The fact that an industry association with no stake in coal mining can hold up lifesaving protections for coal miners is outrageous. The Department of Labor and MSHA should be fighting to implement this rule immediately, not kicking enforcement down the road yet again. Every day they delay, more miners get sick, and more miners die. That's the truth.' Black lung has no cure. Experts say the most effective way to stop the disease from forming or from evolving into a more complicated case is to limit exposure to silica dust. The finalized silica dust rule, if implemented, would cut the exposure limits for coal miners in half for the first time ever. It would also impose new penalties for mines that operate out of compliance and require companies to offer free medical monitoring for their workers with the hope of detecting black lung and other respiratory diseases earlier. Coal miners and advocates for people with black lung have been directly fighting since at least 2009 for industry protections against the disease. Rebecca Shelton, director of policy for the Appalachian Citizens' Law Center, said the continued delay of the rule shows that 'the Trump Administration and the coal companies are seemingly working hand-in-hand to slow down the process and weaken future protections.' 'These delays and efforts to weaken the rule are a disgrace, and undermine the claims of anyone in the Trump Administration who claims to be on the side of coal miners,' Shelton said. While the rule is being continuously delayed, President Donald Trump has called for the country to increase coal production. But coal miners in Central Appalachia and beyond are already seeing higher rates of black lung than any time in the previous 25 years, according to the Centers for Disease Control and Prevention. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX The disease is also hitting coal miners at younger ages than ever before due to a lack of easily accessible coal. Today, miners must cut through more layers of silica-rich sandstone to reach the coal that remains in existing seams, creating dustier conditions that increases their risk of developing black lung. 'Every American worker deserves to come home from work with their lungs intact, miners included,' Roberts said. 'It's as simple as that.' West Virginia Watch is a sister outlet of the Pennsylvania Capital-Star and part of States Newsroom, a nonprofit news network supported by grants and a coalition of donors as a 501c(3) public charity.
